All 1 tracked stories fall under one category: fda-approval. Alcon Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention GenDrive, all published on August 18, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about GenDrive
All 1 tracked stories fall under one category: fda-approval. Alcon Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention GenDrive, all published on August 18, 2026. Each carries 2 original sources on average.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering GenDrive. Shared-story counts are live from our verified record — not editorial picks.
Alcon posted 7% constant-currency sales growth and raised full-year core EPS guidance to 12-15% growth, but took a $402M noncash charge to discontinue PowerVision. Hims & Hers added branded weight-loss momentum with $753M revenue.